open access

Vol 69, No 3-4 (2019)
Review articles
Published online: 2019-10-31
Get Citation

Long-term responses to molecularly targeted treatment and immunotherapy – groups of patients, management

Paweł Rogala, Katarzyna Kozak
DOI: 10.5603/NJO.2019.0023
·
Nowotwory. Journal of Oncology 2019;69(3-4):117-124.

open access

Vol 69, No 3-4 (2019)
Review articles
Published online: 2019-10-31

Abstract

The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma re­sulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment are more likely to benefit from treatment.

Abstract

The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma re­sulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment are more likely to benefit from treatment.

Get Citation

Keywords

ipilimumab; pembrolizumab; nivolumab; dabrafenib; trametinib; long-term survival; melanoma

About this article
Title

Long-term responses to molecularly targeted treatment and immunotherapy – groups of patients, management

Journal

Nowotwory. Journal of Oncology

Issue

Vol 69, No 3-4 (2019)

Pages

117-124

Published online

2019-10-31

DOI

10.5603/NJO.2019.0023

Bibliographic record

Nowotwory. Journal of Oncology 2019;69(3-4):117-124.

Keywords

ipilimumab
pembrolizumab
nivolumab
dabrafenib
trametinib
long-term survival
melanoma

Authors

Paweł Rogala
Katarzyna Kozak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl